Tesamorelin is another compound where "FDA-approved" gets repeated online without the actual approved indication ever getting mentioned, and that indication is a lot narrower than the general fat-loss framing suggests.
What tesamorelin is
Tesamorelin is a synthetic growth hormone-releasing factor (GRF) analog. It works by stimulating the body's own pituitary gland to release growth hormone, rather than supplying growth hormone directly. It's marketed as a prescription pharmaceutical under the brand name Egrifta.
What's actually been studied
- HIV-associated lipodystrophy. Tesamorelin's approval is specifically for reducing excess visceral abdominal fat in adults with HIV who have lipodystrophy, a fat-redistribution condition linked to HIV and some antiretroviral treatments. A controlled 26-week trial reported a meaningfully larger reduction in visceral fat with tesamorelin than with placebo, and a pooled analysis of two phase 3 trials in this specific population found a substantial treatment effect at 26 weeks (HIV i-Base summary of the FDA approval and trial data).
- Regulatory record. The FDA approved tesamorelin (Egrifta) in November 2010 as the first approved treatment for HIV-associated lipodystrophy, and later approved a reformulated version, Egrifta WR, for the same indication (Contagion Live, on the F8 reformulation approval).
Where the evidence is thin
The approved trial evidence is specific to one population: adults with HIV-associated lipodystrophy. That's a distinct clinical picture from general visceral fat or "belly fat" in people without HIV, and I was not able to find equivalent large randomized trial evidence establishing the same effect size in a general population using tesamorelin for cosmetic or general fat-loss purposes. Extending a result from a specific patient population to a general one is exactly the kind of leap that gets made in online discussion of this compound without the caveat attached.
The regulatory picture
Tesamorelin (Egrifta) is FDA-approved specifically for HIV-associated lipodystrophy, under physician supervision, not for general fat loss in the broader population. The research-chemical version sold for laboratory research is a different product from the approved pharmaceutical, and using it outside that approved, supervised context isn't something the approval or the underlying trials cover. It's sold by research chemical vendors strictly for laboratory research, not for human use.
Papa's take
The visceral-fat trial data is real, and it's specific. What bothers me about how tesamorelin gets talked about online is the quiet substitution of "reduces visceral fat in HIV-associated lipodystrophy" with "reduces belly fat," as if those were interchangeable claims backed by the same evidence. They aren't, and the population the trials were actually run in matters as much as the result itself.
Sources
- FDA approves tesamorelin for reduction of central fat accumulation, HIV i-Base
- FDA Approves F8 Formulation of Theratechnologies' Tesamorelin for HIV-Associated Lipodystrophy, Contagion Live
Sourcing for research
If you're sourcing tesamorelin for laboratory research, purity documentation matters. See my vendor comparisons for how I evaluate third-party certificates of analysis.